Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach

BackgroundSevere acute respiratory syndrome (SARS)-CoV is a newly emerging virus that causes SARS with high mortality rate in infected people. Successful control of the global SARS epidemic will require rapid and sensitive diagnostic tests to monitor its spread, as well as, the development of vaccines and new antiviral compounds including neutralizing antibodies that effectively prevent or treat this disease.MethodsThe human synthetic single-chain fragment variable (scFv) ETH-2 phage antibody library was used for the isolation of scFvs against the nucleocapsid (N) protein of SARS-CoV using a bio panning-based strategy. The selected scFvs were characterized under genetics-molecular aspects and for SARS-CoV N protein detection in ELISA, western blotting and immunocytochemistry.ResultsHuman scFv antibodies to N protein of SARS-CoV can be easily isolated by selecting the ETH-2 phage library on immunotubes coated with antigen. These in vitro selected human scFvs specifically recognize in ELISA and western blotting studies distinct epitopes in N protein domains and detect in immunohistochemistry investigations SARS-CoV particles in infected Vero cells.ConclusionThe human scFv antibodies isolated and described in this study represent useful reagents for rapid detection of N SARS-CoV protein and SARS virus particles in infected target cells.

• Publication year

  2005

• Venue

  BMC Infectious Diseases

• Publication date

  2005-09-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1471-2334-5-73PMID 16171519PMCID 1261265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike Glycoprotein

  2005cited by this paper
• Recombinant protein‐based ELISA and immuno‐cytochemical assay for the diagnosis of SARS†

  2005cited by this paper
• Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library

  2005cited by this paper
• Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants

  2005cited by this paper
• Severe acute respiratory syndrome

  2004cited by this paper
• Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid

  2004cited by this paper
• Isolation and Characterization of the Human Monoclonal Antibodies C10 in Single-Chain Fragment Variable (scFv) Format to Glucose Oxidase from Aspergillus niger

  2004cited by this paper
• Laboratory diagnosis of SARS.

  2004cited by this paper
• Recombinant scFv Antibodies against E Protein and N Protein of Severe Acute Respiratory Syndrome Virus

  2004cited by this paper
• The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain

  2004cited by this paper
• Immunogenicity of SARS inactivated vaccine in BALB/c mice

  2004cited by this paper
• Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS

  2004cited by this paper
• Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis.

  2003cited by this paper
• Treatment of severe acute respiratory syndrome with convalescent plasma.

  2003cited by this paper
• The Severe Acute Respiratory Syndrome

  2003cited by this paper
• Neutralizationof Enteric Coronaviruses with Escherichia coli CellsExpressing Single-Chain Fv-AutotransporterFusions

  2003cited by this paper
• Generation of chicken single chain antibody variable fragments (scFv) that differentiate and neutralize infectious bursal disease virus (IBDV)

  2003cited by this paper
• Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus

  2003cited by this paper
• Design and use of phage display libraries for the selection of antibodies and enzymes.

  2000influential reference
• The selection of intracellular antibodies.

  1998cited by this paper
• Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.

  1996cited by this paper

• Exploring phage engineering to advance nanobiotechnology

  2022cites this paper
• Construction, Characterization, and Application of a Nonpathogenic Virus-like Model for SARS-CoV-2 Nucleocapsid Protein by Phage Display

  2022cites this paper
• Development of therapeutic antibodies for the treatment of diseases

  2020cites this paper
• On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies

  2020cites this paper
• The immune vulnerability landscape of the 2019 Novel Coronavirus, SARS-CoV-2

  2020cites this paper
• Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity

  2019cites this paper
• The Nucleocapsid Protein of the SARS Coronavirus: Structure, Function and Therapeutic Potential

  2009cites this paper
• Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1.

  2009cites this paper
• Selection of phage-displayed human antibody fragments on Dengue virus particles captured by a monoclonal antibody: application to the four serotypes.

  2008cites this paper
• Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein

  2007cites this paper
• The SARS-CoV nucleocapsid protein: A protein with multifarious activities

  2007cites this paper
• Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen.

  2007cites this paper
• In vitro display technologies reveal novel biopharmaceutics

  2006cites this paper
• Isolation of an scFv targeting BRG1 using phage display with characterization by AFM.

  2006cites this paper